Immunocore Holdings plc

IMCR · Nasdaq · United Kingdom

Share price · IMCR

$27.51-8.51 (-23.63%) 3M

close as of 2026-11-18 · 24h delayed · vol 297K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IMCR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+9.1%
  2. 29 Oct 2026-4.1%
  3. 20 Oct 2026+9.2%
  4. 22 Jul 2026+3.1%

    Nothing announced by IMCR that day or the session before.

  5. 30 Jun 2026+4.4%

    Nothing announced by IMCR that day or the session before.

  6. 3 Jun 2026-3.1%
  7. 8 May 2026-3.4%

    Nothing announced by IMCR that day or the session before.

  8. 6 May 2026+6.6%
  9. 21 Apr 2026-6.2%
  10. 6 Apr 2026+3.6%

    Nothing announced by IMCR that day or the session before.

Share of unusual movement by asset

For each asset, the share of IMCR's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
tebentafusp-tebn (KIMMTRAK)
events and moves
2shown from 8 days
brenetafusp
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—85%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
gp100-HLA-A*02:01 x CD3Protein / enzyme therapeutic
Uveal MelanomaMelanoma
Unresectable or Metastatic Uveal Melanoma
Phase 3
PRAME antigen presented on HLA-A*02:01Protein / enzyme therapeutic
Melanoma
Cutaneous Melanoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
brenetafuspPhase 3Advanced Melanoma
Est. primary completion 2027-10-16 · NCT06112314 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
tebentafusp-tebn · KIMMTRAKPhase 3Advanced Melanoma
Est. primary completion 2028-03 · NCT05549297 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$102M$75M$512M+ $389M short-term inv.$14M$20M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$116M$74M$485M+ $395M short-term inv.$0.8M$16M operating cash flowreport ↗
2026-Q1$107M$61M$453M+ $392M short-term inv.—-$14M operating cash flowreport ↗
2025-Q3$104M$71M$498M+ $394M short-term inv.$0.2M-$4.5M operating cash flowreport ↗
2025-Q2$98M$69M$488M+ $395M short-term inv.$10M$26M operating cash flowreport ↗
2025-Q1$94M$56M$477M+ $360M short-term inv.—$0.4M operating cash flowreport ↗
2024-Q3$80M$53M$538M+ $364M short-term inv.—$21M operating cash flowreport ↗
2024-Q2$75M$51M$505M+ $355M short-term inv.$12M$23M operating cash flowreport ↗
2024-Q1$71M$57M$833M$24M-$4.6M operating cash flowreport ↗
2023-Q3—$43M$444M—$10M operating cash flowreport ↗
2023-Q2—$38M$432M$17M$0.1M operating cash flowreport ↗
2023-Q1—$37M$418M$19M$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$400M$275M$468M+ $396M short-term inv.$8.9M-$11M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$310M$222M$456M+ $365M short-term inv.$13M$26M operating cash flowreport ↗
2023-FY$239M$164M$443M+ $0 short-term inv.$14M$2.9M operating cash flowreport ↗
2022-FY$141M$102M$402M$13M-$49M operating cash flowreport ↗
2021-FY$4.1M$100M$321M$45M-$143M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($5.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-27Bell John Irving · directorAward / grant (derivative)27,492——Form 4
2026-05-27Herbst Roy Steven · directorAward / grant (derivative)27,492——Form 4
2026-05-27Kaul Siddharth · directorAward / grant (derivative)27,492——Form 4
2026-05-27Pao William · directorAward / grant (derivative)27,492——Form 4
2026-05-27Peterson Kristine · directorAward / grant (derivative)27,492——Form 4
2026-05-27Ratcliffe Peter John · directorAward / grant (derivative)27,492——Form 4
2026-02-18Berman David M · HEAD OF R&DOpen-market sale5,965$32.35$193KForm 4
2026-02-18St Leger Tina Amber · CHIEF HR OFFICEROpen-market sale1,000$32.35$32KForm 4